Bridging the Gap: Advancing First-Line Therapy for Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
0/5 보강
APA
Valenza C, Nixon NA, et al. (2026). Bridging the Gap: Advancing First-Line Therapy for Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2502942. https://doi.org/10.1200/JCO-25-02942
MLA
Valenza C, et al.. "Bridging the Gap: Advancing First-Line Therapy for Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.." Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026, pp. JCO2502942.
PMID
41570276 ↗
같은 제1저자의 인용 많은 논문 (4)
- Optimizing adjuvant endocrine therapy in premenopausal patients with HER2-positive, hormone receptor-positive breast cancer.
- Inadequate ovarian function suppression and endocrine therapy manipulations in premenopausal patients with early breast cancer on adjuvant LHRH agonist and aromatase inhibitor: a cohort study.
- Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort Study.
- Lessons From the SONIA Trial on Timing of CDK4/6 Inhibitors in Advanced Breast Cancer-The Sooner, the Better?